Valuation: vTv Therapeutics Inc.

Market Cap 380M 337M 315M 287M 541M 36.51B 546M 3.81B 1.48B 18.67B 1.43B 1.4B 59.91B P/E 2026 *
-14.3x
P/E 2027 * -6.71x
Enterprise Value 380M 337M 315M 287M 541M 36.51B 546M 3.81B 1.48B 18.67B 1.43B 1.4B 59.91B EV / Sales 2026 *
12.9x
EV / Sales 2027 * -
Free-Float
61.17%
Yield 2026 *
-
Yield 2027 * -
1 day-4.02%
1 week+1.19%
Current month-0.88%
1 month-8.66%
3 months-13.64%
6 months-25.75%
Current year-23.56%
1 week 29.68
Extreme 29.675
32.32
1 month 29.68
Extreme 29.675
34.14
Current year 28.75
Extreme 28.75
44
1 year 19.5
Extreme 19.5
44
3 years 7.38
Extreme 7.38
44
5 years 7.38
Extreme 7.38
67.2
10 years 7.38
Extreme 7.38
336
Manager TitleAgeSince
Chief Executive Officer 68 01/08/2022
Director of Finance/CFO 50 19/05/2025
Chief Tech/Sci/R&D Officer - 02/11/2023
Director TitleAgeSince
Director/Board Member 56 16/11/2020
Director/Board Member 48 11/07/2022
Chairman 68 01/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
26/06/26 Free

Director

6,000 0.1523%
17/02/26 Free

Chief Financial Officer

44,969 1.1419%
17/02/26 Free

Chief Executive Officer

140,000 3.5551%
Change 5-day change 1-year change 3-year change Capi.($)
-4.02%+1.19%+26.85%+62.61% 380M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.60%-0.41%+50.06%+121.95% 39.09B
Weighted average by Cap. +0.12%-0.84%+56.93%+138.19%

Financials

2026 *2027 *
Net sales 29.48M 26.19M 24.45M 22.28M 42.02M 2.83B 42.42M 296M 115M 1.45B 111M 108M 4.65B -
Net income -26.7M -23.72M -22.14M -20.18M -38.06M -2.57B -38.41M -268M -104M -1.31B -100M -98.06M -4.21B -68.02M -60.44M -56.41M -51.42M -96.97M -6.54B -97.87M -683M -265M -3.34B -255M -250M -10.73B
Net Debt - -
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change Volume
02/10/26 $30.57 -4.02% 18,015
01/10/26 $31.85 +3.27% 34,271
30/09/26 $30.84 +2.80% 30,937
29/09/26 $30.00 -1.70% 85,142
28/09/26 $30.52 +1.03% 111,861
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
30.57USD
Average target price
54.71USD
Spread / Average Target
+78.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTVT Stock